We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Gilead Sciences Inc | NASDAQ:GILD | NASDAQ | Common Stock |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| -0.54 | -0.83% | 64.79 | 64.30 | 64.85 | 65.53 | 64.33 | 65.51 | 7,822,721 | 05:00:04 |
From May 2019 to May 2024
By Dave Sebastian
Gilead Science Inc. (GILD) and Galapagos NV (GLPG) said Thursday that its marketing authorization application for filgotinib, a treatment for rheumatoid arthritis, is being evaluated by the European Medicines Agency.
The application is based on 24-week data from the treatment's phase 3 clinical trials that demonstrated improvements in arthritis signs and symptoms, the companies said.
The EMA is a European Union agency that evaluates and approves medicinal products for its 28 members as well as Norway, Iceland and Liechtenstein.
Gilead has announced plans to submit a new drug application to the Food and Drug Administration for the treatment by the end of the year.
Gilead said in July it will pay $5.1 billion to boost its stake in Galapagos and gain rights outside Europe to the Belgian biotechnology company's treatments in development.
Write to Dave Sebastian at dave.sebastian@wsj.com
(END) Dow Jones Newswires
August 15, 2019 17:08 ET (21:08 GMT)
Copyright (c) 2019 Dow Jones & Company, Inc.
1 Year Gilead Sciences Chart |
1 Month Gilead Sciences Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
